Pediatric Advisory Committee; Amendment of Notice, 10909 [2017-03144]

Download as PDF Federal Register / Vol. 82, No. 31 / Thursday, February 16, 2017 / Notices Dated: February 13, 2017, William N. Parham, III, Director, Paperwork Reduction Staff, Office of Strategic Operations and Regulatory Affairs. [FR Doc. 2017–03135 Filed 2–15–17; 8:45 am] BILLING CODE 4120–01–P This notice is issued under the Federal Advisory Committee Act (5 U.S.C. app. 2) and 21 CFR part 14, relating to the advisory committees. DEPARTMENT OF HEALTH AND HUMAN SERVICES Dated: February 13, 2017. Janice M. Soreth, Associate Commissioner for Special Medical Programs. Food and Drug Administration [Docket No. FDA–2017–N–0001] Pediatric Advisory Committee; Amendment of Notice AGENCY: [FR Doc. 2017–03144 Filed 2–15–17; 8:45 am] BILLING CODE 4164–01–P Food and Drug Administration, HHS. ACTION: (1) Center for Drug Evaluation and Research (CDER) a. NITROPRESS (sodium nitroprusside) b. KUVAN (sapropterin dihydrochloride) DEPARTMENT OF HEALTH AND HUMAN SERVICES Notice. The Food and Drug Administration (FDA) is announcing an amendment to the notice of meeting of the Pediatric Advisory Committee. This meeting was announced in the Federal Register of January 5, 2017. The amendment is being made to reflect a change in the Center for Drug Evaluation and Research (CDER) products portion of the document. There are no other changes. FOR FURTHER INFORMATION CONTACT: Marieann Brill, Office of the Commissioner, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 32, Rm. 5154, Silver Spring, MD 20993, 240–402–3838, email: marieann.brill@fda.hhs.gov, or FDA Advisory Committee Information Line, 1–800–741–8138 (301–443–0572 in the Washington, DC area). Please call the Information Line for up-to-date information on this meeting. SUPPLEMENTARY INFORMATION: In the Federal Register of January 5, 2017 (82 FR 1345), FDA announced that a meeting of the Pediatric Advisory Committee (PAC) would be held on March 6 and 7, 2017. On page 1346, in the third column, the CDER products portion of the document is changed to read as follows: On March 6, 2017, the PAC will meet to discuss the following products (listed by FDA Center): SUMMARY: Office of the Secretary [Document Identifier: 0990–New–60D] Agency Information Collection Activities; Proposed Collection; Public Comment Request Office of the Secretary, HHS. Notice. AGENCY: ACTION: In compliance with section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, the Office of the Secretary (OS), Department of Health and Human Services, announces plans to submit a new Information Collection Request (ICR), described below, to the Office of Management and Budget (OMB). Prior to submitting the ICR to OMB, OS seeks comments from the public regarding the burden estimate below or any other aspect of the ICR. DATES: Comments on the ICR must be received on or before April 17, 2017. ADDRESSES: Submit your comments to Information.Collection Clearance@hhs.gov or by calling (202) 690–5683. SUPPLEMENTARY INFORMATION: When submitting comments or requesting information, please include the document identifier 0990–New–60D for reference. SUMMARY: 10909 Information Collection Request Title: National Council for Behavioral Health’s Information Technology Survey. Abstract: The Office of the National Coordinator for Health IT (ONC), in coordination with Substance Abuse and Mental Health Services Administration (SAMHSA) seeks to conduct a survey annually for the next three years to examine trends in the adoption and use of health IT as well as interoperability across community behavioral health care settings. Data from the survey will help ONC and SAMSHA monitor progress and enhance programs and policy to improve the use of health IT and expand interoperability across these settings. In 2015, ONC outlined a strategy by which both private and public stakeholders would work together to improve interoperability. This strategy called for measuring and reporting on the state of interoperability across the care continuum, including for behavioral health care providers; however, there are no recent national data available for this care setting. Addressing this gap is critical in order to also determine these providers’ readiness to serve as partners in delivery system reform efforts that are underway and that will be expanded with the implementation of Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Although behavioral health care providers won’t be participating in the MACRA initiative at the outset, the Secretary of Health and Human Services may include behavioral health providers, such as psychologists and social workers to participate in value-based payment initiatives such as the Merit-Based Incentive Payment System (MIPs) in the future. Likely Respondents: The respondents will include mid-level and executive level staff (IT Directors, CIO, and CEOs) of behavioral healthcare organizations that are involved in the management and maintenance of their organization’s health IT infrastructure. The total annual burden hours estimated for this ICR are summarized in the table below. asabaliauskas on DSK3SPTVN1PROD with NOTICES TOTAL ESTIMATED ANNUALIZED BURDEN—HOURS Form name Number of respondents Number of responses annually per respondent Total responses per year Average hours per response Total burden hours National Council for Behavioral Health’s Information Technology Survey ................................................................... 2,700 1 2,700 20/60 900 VerDate Sep<11>2014 19:05 Feb 15, 2017 Jkt 241001 PO 00000 Frm 00039 Fmt 4703 Sfmt 4703 E:\FR\FM\16FEN1.SGM 16FEN1

Agencies

[Federal Register Volume 82, Number 31 (Thursday, February 16, 2017)]
[Notices]
[Page 10909]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-03144]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2017-N-0001]


Pediatric Advisory Committee; Amendment of Notice

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is announcing an 
amendment to the notice of meeting of the Pediatric Advisory Committee. 
This meeting was announced in the Federal Register of January 5, 2017. 
The amendment is being made to reflect a change in the Center for Drug 
Evaluation and Research (CDER) products portion of the document. There 
are no other changes.

FOR FURTHER INFORMATION CONTACT: Marieann Brill, Office of the 
Commissioner, Food and Drug Administration, 10903 New Hampshire Ave., 
Bldg. 32, Rm. 5154, Silver Spring, MD 20993, 240-402-3838, email: 
marieann.brill@fda.hhs.gov, or FDA Advisory Committee Information Line, 
1-800-741-8138 (301-443-0572 in the Washington, DC area). Please call 
the Information Line for up-to-date information on this meeting.

SUPPLEMENTARY INFORMATION: In the Federal Register of January 5, 2017 
(82 FR 1345), FDA announced that a meeting of the Pediatric Advisory 
Committee (PAC) would be held on March 6 and 7, 2017. On page 1346, in 
the third column, the CDER products portion of the document is changed 
to read as follows:
    On March 6, 2017, the PAC will meet to discuss the following 
products (listed by FDA Center):

(1) Center for Drug Evaluation and Research (CDER)
    a. NITROPRESS (sodium nitroprusside)
    b. KUVAN (sapropterin dihydrochloride)

    This notice is issued under the Federal Advisory Committee Act (5 
U.S.C. app. 2) and 21 CFR part 14, relating to the advisory committees.

    Dated: February 13, 2017.
Janice M. Soreth,
Associate Commissioner for Special Medical Programs.
[FR Doc. 2017-03144 Filed 2-15-17; 8:45 am]
 BILLING CODE 4164-01-P